Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Oak Tree who wrote (2773)	2/2/2001 12:37:48 AM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

<<I think that radiation will still be needed since I have less confidence in the drug coatings.>> In the Febr. Issue of Clinical Cardiology: 24, 119-126 (2001)there is an article by Antonis S. Manolis,M.D..FACC,FESC from Patras Univ. in Greece entitled: Reduced Incidence of Clinical Restenosis with Newer Generation Stents, Stent Oversizing, and High-Pressure Deployment. He presented a series of 244 consecutive patients (203 men and 41 women) 83 patients had only PTCA and 161 patients also received stents.Quite a different variety, (J&J, NIR, ACS, AVE, Inflow-Goldflex, Crossflex, Wictor, Josten, Seaquence, and Wallstent There was 18 +/- 14 months of follow-up and he concluded that with the newer generation stents and a consistent approach of stent oversizing and high-pressure stent deployment the procedural success was 99%, there was 0% of stent thrombosis and the rate of clinical restenosis was low at 7%(The PTCA group had 28.4% restenosis with p=0.001) By the way, there is a meeting of the Cardiovascular Radiation Therapy and Restenosis Forum on Febr.5-7 in Washington, D.C. Bernard